What is Bio Link?
Bio Link International Inc. is a key player in the biomedical solutions industry, specializing in the development and manufacturing of diagnostic tools and reagents for scientific research. The company's product portfolio includes a comprehensive range of recombinant antigens for critical diseases such as HIV, HCV, and Syphilis. These high-quality antigens are engineered for precision in various diagnostic tests, including EIA, ELISA, and RIPA, ensuring both sensitivity and specificity. Bio Link is dedicated to empowering the research community with cost-effective, top-tier products essential for advancing disease research and combating global health challenges.
How much funding has Bio Link raised?
Bio Link has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Bio Link?
With its recent large-scale, late-stage funding, Bio Link is strategically positioned for significant expansion and innovation. The substantial capital infusion, highlighted by the recent major strategic investment, will likely fuel advancements in its diagnostic manufacturing capabilities and broaden its research into new biomedical frontiers. This financial backing is expected to accelerate the development and deployment of its specialized recombinant antigens, further solidifying its role in scientific research and diagnostic testing, and potentially enabling entry into new therapeutic areas or geographical markets.
See full Bio Link company page
